Keywords
Excessive menstrual bleeding, polymorphism, vascular endothelial growth factor, VEGF gene
Posted Date: May 5th, 2021
DOI: https://doi.org/10.21203/rs.3.rs-459616/v1
License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full
License
Version of Record: A version of this preprint was published at Archives of Gynecology and Obstetrics on September
8th, 2021. See the published version at https://doi.org/10.1007/s00404-021-06225-1.
Page 2/14
Abstract
Purpose: To investigate whether there is a relationship between the VEGF gene polymorphisms and idiopathic heavy
menstrual bleeding (HMB-E).
Methods
65 patients diagnosed with HMB-E according to the FIGO classication system and 65 female healty
volunteers were included in the study. Detection of rs699947 (-2578C>A), rs1570360 (-1154G>A), rs2010963
(+405G>C), rs3025039 (+936C>T), rs25648 (c534C>T) polymorphic regions of the VEGF gene was performed by Next
Generation DNA Sequencing method.
Results
the -2578C>A polymorphic region CC, CA+AA genotypes, and C allele, as well as the -1154G>A polymorphic
region AA genotype, and A allele were associated with increased risk of HMB-E (all pC, +936C>T, c534C>T polymorphic regions (all p>0.05). While the -2578/-1154/+405/c534
AGGC haplotype decreased the risk of HMB-E, CAGC haplotype was found to increase the risk of HMB-E.
Conclusion
VEGF -2578C>A and -1154G>A polymorphisms were signicantly associated with the risk of HMB-E in the
Turkish population.
Introduction
Heavy menstrual bleeding (HMB) is an important health problem dened as menstruation at regular intervals but with
excessive ow and duration. Clinically, it is dened as a blood loss of more than 80 ml per cycle. It is a common
gynecological problem among women of reproductive age and accounts for more than 20% of outpatient visits to
gynecologists [1]. Although HMB is often associated with uterine pathology (e.g., broid, polyp, adenomyosis,
carcinoma), abnormal blood clotting or disruption of hormonal regulation, approximately 50% of HMB cases occur in
the absence of recognized uterine pathology [2,3], suggesting a defect in the cellular processes and regulatory
mechanisms of menstruation. Such idiopathic HMB of endometrial origin (HMB-E) has been estimated to account for
9-14% of gyneco logical outpatient visits [4,5].
HMB can lead to iron deciency anemia. Current treatment options often compromise fertility, and may require
hysterectomy in patients who do not respond to the treatments [6]. Another problem is increased maternal morbidity
and mortality for pregnant women who has HMB-associated anemia. Heavy bleeding can affect daily activities. Need
for long-term medication, the side effects of these therapies, and the intolerance can cause psychological and social
discomfort. Also for numerous female individuals, problems related to employment have led to the designation of
HMB as a public health problem [4].
Disturbance of endometrial angiogenesis is one of several proposed underlying mechanisms that have been
suggested to play a role in HMB [4,5]. In the formation of functional and stable micro vessels, covering the luminal
surface of endothelial tubes with mesenchymal pericytes is an important step. The pericytes interact tightly and
adhere to the endothelial cells with the pores in the basal layer [7]. Pericytes may induce angiogenesis with Vascular
Endothelial Growth Factor (VEGF) production which stimulates endothelial cell proliferation and tube formation.
Previous studies have shown that The biopsy specimens of women with HMB have revealed that number of
capillaries expressing VEGF-A and its receptors (VEGFR-1 and VEGFR-2) were signicantly higher in patients with
HMB compared to healthy controls [1]. It is known that glandular luminal surfaces of patients with HMB are wider and
this nding is highly correlated with overexpression of VEGF-A and VEGFR-1 [8]. It is suggested that the mesenchymal
pericytes acting on the basis of angiogenesis may contribute to the vascular fragility. This leads to excessive blood
Page 3/14
loss due to extensive endothelial cell gaps and abnormal vascular remodeling as a result of inappropriate coverage of
the laminal surface of endothelial tubes [8,9].
In the literature, there is no study investigating the VEGF polymorphism in patients with idiopathic HMB-E. The
evidence of the presence of VEGF polymorphism in patients with HMB-E may provide new opportunities for future
research and treatment options. Thus, patients and doctors will avoid the risks of unnecessary surgeries. We therefore
planned to investigate the relationship between VEGF polymorphism and idiopathic HMB-E.
Materials and methods
Our study is a cross-sectional study conducted from February 2019 to March 2020. It was approved by the Ankara
Yıldırım Beyazıt University Yenimahalle Training and Research Hospital Clinical Research Ethics Committee on the
date of 29.01.2019 and with the decision number of 2019/01/01 and complied with the Helsinki Declaration,
including current revisions and the Good Clinical Practice guidelines.
Power analysis of the study showed that 128 patients were needed to gain 80% power when α error was set at 0.05, β
error at 0.05, and effect size at 0.50.
A total of 65 patients between the ages of 18-45 who were admitted with the complaint of abnormal uterine bleeding
and diagnosed with idiopathic HMB according to the FIGO Classication System [10] and 65 voluntary women with
regular menstruation were included in the study. All participants were informed about the study and consent forms
were signed.
The participants were selected according to the dened inclusion criteria: 18 to 45 years old, having a regular
menstrual cycle between 24 - 38 days, not using hormonal or intrauterine contraception for at least three months prior
the study, no abnormal ultrasonographic or hysteroscopic ndings, not pregnant and not lactating.
Women were excluded from the study if they had a uterine pathology (such as polyp, adenomyosis, leiomyoma,
malignancy, hyperplasia), had a history of signicant medical problems (such as coagulopathies, hypothyroidism,
hyperprolactinemia, Polycystic ovary syndrome, endometriosis), smokers, taken any medicines that increases the
tendency to bleeding.
For patient selection according to these criteria all participants were evaluated based on a complete medical,
gynecological and obstetric history and gynecological examination with ultrasound assessment. Additionally,
hysteroscopy or dilatation and curettage was performed in the presence of suspicion of endometrial pathology.
Menstrual blood loss was evaluated with Pictorial Blood loss Assessment Chart (PBAC) which has a a positive
predictive value of 85.9% in diagnosing menorrhagia and with a good correlation to alkaline hematin method [11,12].
Self-evaluated PBAC consists of diagrams representing different soiled pads or tampons each day and pads were
scored according to the degree of staining and the size of the clots on it. Women with a PBAC score > 100 were
included in the HMB group and healthy, ovulating women with a PBAC score A, in the promoter region), rs1570360 (-1154G>A, in the promoter region)
rs2010963 (+405G>C, at 5′UTR), rs3025039 (+936C>T, at 3'UTR), rs25648 (c534C>T, at exon1) and checked in
Ensemble, dbSNP database.
Page 4/14
Peripheral venous blood samples were collected from all subjects and transferred to EDTA tubes. Samples were
stored frozen at -20°C until they were studied.
Laboratory studies were carried out in the INTERGEN Genetic and Rare Diseases Diagnosis Research and Application
Center.
DNA extraction and genotyping: DNA extraction was performed from 200 µl peripheral blood with spin column
Method
using HibriGen Blood DNA isolation kit ( İ stanbul, Turkey). The isolates were measured with Nanodrop 1000
(Thermo Inc.) microvolume spectrophotometer and the study continued with samples containing 10 ng / µl and more.
Primer design was made for PCR amplication of all coding region and exon-intron junction regions of VEGFA gene
and 4 polymorphisms (rs699947, rs1570360, rs2010963, rs3025039). Primers, amplicon size and usage purposes are
shown in table 1.
Amplication of the regions was achieved by using the isolated DNA and the designed primers in the PCR reaction.
Amplication eciency was evaluated by visualizing the reaction results with 2% agarose gel electrophoresis. PCR
pools were created by combining the PCRs of each sample and then puried by NucleoFast® 96 PCR kit (MACHEREY-
NAGEL GmbH). The puried samples were quantitated by a spectrophotometer (Nanodrop N1000, Thermo Inc.). The
amount of DNA was determined and diluted to 5 ng / µl.
Detection of polymorphisms was performed by NGS (Next Generation DNA Sequencing) method using Miseq device
(Illumina Inc. San Diego, CA, USA). Standardized samples were prepared for next generation sequencing using the
Nextera XT sample preparation kit (Illumina Inc.). DNA Library preparations were made according to the determined
instructions. A sample worksheet le was created to introduce the study to the device. All of the prepared samples
were loaded into the sample loading compartment in the Miseq Reagent Kit v2 2x150 (MS-102-2002, Illumina Inc.)
cartridge. After all the preparations and controls were made, the Miseq device was started. Approximately 24 hours
later, study results were taken and analyzed. Alignment of the obtained readings was done with Miseq Reporter
(illumina Inc.) software on human genome hg19 version. Analysis of the aligned bam les was performed using IGV
2.3 (Broad Institute) software.
Statistical Analyses
Continuous variables were rst inspected for normality of statistical distribution graphically and by Shapiro–Wilk test.
Data were reported as mean ± standard deviation (SD), median with interquartile ranges (IQRs) or numbers and
percentages, as appropriate. The data were analyzed using the Student’s t test, Mann–Whitney test or chi square test
to determine the signicance of the differences between the groups. The Chi-square test was used to assess the
variation in each SNP frequency from Hardy–Weinberg equilibrium (HWE). Logistic regression analysis models were
used to calculate the odds ratio (OR) and 95% condence interval (CI), thereby assessing the effect of genotypes on
HMB risk. These analyzes were calculated with IBM SPSS 25 and the epitools package in R 3.6.1 program. The
haplotype of VEGF polymorphisms was analyzed by using SHEsis. The linkage disequilibrium of genotype and allele
pairs was calculated via the Haploview version 4.2 (Broad Institute, Cambridge, MA, USA).Statistical signicance was
set at P ≤ 0.05.
Results
Baseline characteristics
Page 5/14
The baseline characteristics of the subjects are summarized on Table 2. There were no differences in age, Body Mass
Index (BMI), marital status, gravidity, parity, age at menarche, length of menstrual cycle between the analyzed groups.
Compared with the control group, as aspected the patients in HMB group presented signicant increases in menses
duration and PBAC score.
Genotype and allele distribution of VEGF polymorphisms
The genotype frequency distribution of the selected population were found to be compatible in Hardy-Weinberg
equilibrium (p > 0.05), suggesting it represents the population.
As shown in Table 3, the risk of having HMB in individuals with the VEGF gene −2578A>C polymorphic region CC
genotype was 3.05 times higher, the AC + CC genotype was 2.35 times higher compared with the AA genotype, C allele
was 1.75 times higher compared with A allele (CC vs AA, OR = 3.05, 95% CI = 1.11-8.84, p = 0.025; AC + CC vs AA, OR =
2.35, 95% CI = 0.97-6.0, p = 0.051; C vs A, OR = 1.75, 95% CI = 1.07-2.88, p = 0.024). In comparison with the −1154G>A
polymorphic region GG genotype, AA genotype is related to 3.49 times higher risk of HMB and in comparison with G
allele, A allele is related to 1.74 times higher risk og HMB (AA vs GG, OR=3.49, % 95 CI=0.89-18.10, P = 0.06; A vs G,
OR=1.74, % 95 CI =1.01-3.01, P = 0.04). However, the genotype and allele frequency distributions of rs2010963,
rs3025039 and rs25648 were not statistically different between groups (all p > 0.05).
Haplotype analysis for the association between VEGF gene polymorphisms and HMB risk
VEGF gene polymorphisms in linkage disequilibrium analysis including four SNP (-2578C>A, -1154G>A, +405G>C and
534C>T) revealed one SNP block (Figure 1).
We detected four main haplotypes with frequencies greater than 0.03. CACC, AGGC, CAGC, AAGT. These haplotypes
were analyzed with the online software SHEsis and compared between the HMB and the control group (Table 4). The
AGGC haplotype was found to be statistically signicantly lower in the HMB group with a percentage of 23.8% than in
the control group 38.5% (OR = 0.505, 95% CI = 0.295-1.517, p = 0.012). The CAGC haplotype was statistically
signicantly higher in the HMB group with 25.4% and 9.2% in the control group (OR = 3.387, 95% CI 0.481-2.116, p =
0.0005). As a result, it was concluded that AGGC haplotype decreased the risk of HMB and CAGC haplotype increased
the risk of HMB.
Discussion
In this study we aimed to investigate the signicance of SNPs of the VEGF gene (rs699947 (-2578C>A), rs1570360
(-1154G>A) rs2010963 (+405G>C), rs3025039 (+936C>T), rs25648 (c534C>T) in HMB. We have found increased risk
for HMB in patients with CC, AC+CC genotype, and C allele of the -2578C>A polymorphic region and AA genotype and
A allele of the -1154G>A polymorphic region (p C, +936C>T, and c534C>T (p > 0.05).
In the literature, we have not encountered any studies emphasising on the relationship between SNPs and HMB.
Nevertheless, there are several studies investigating the effect of VEGF gene polymorphisms in cardiovascular
diseases, essential hypertension, certain cancer types, psoriasis, and endometriosis. Although being a unique study
represents strength of our work, it also enabled us to discuss or compare our results with similar papers. Therefore, we
compared our ndings with articles about endometriosis, which denes a gynecologic disease that endometrial tissue
is present outside the uterus.
Page 6/14
Perini et al. [13] evaluated -2578C>A, −460T>C, −1154G>A, +405G>C, and +936C>T polymorphisms in 182 Brazilian
women with endometriosis and reported that variant allele -1154A was had signicant relationship with
endometriosis. They found AA genotype in 9.3% of patients and 1.9% of controls while the frequency of GA+AA
genotype was 44.1% in patients and 30.2% in controls, and frequency of A allele was 26.7% in patient group and
16.0% in controls (p < 0.05). In our study, the AA genotype was found in 56.9% of patients and 38.5% of controls while
the frequency of GA+AA genotype was 95.4% for patients and 87.7% for controls and the frequency of A allele was
76.1% in HMB patients and 61.5% in controls (p A polymorphic region and an approximate 6-
fold increased risk for AA genotype. Similarly, we have observed an approximate two-fold increased risk for HMB in
individuals with GA+AA genotype (p > 0.05), an approximate 3.5 fold increase in AA genotype (p = 0.06), and an
approximate two fold increase in case of harbouring A allele (p = 0.04). Although these two studies presents distinct
genotype and allele frequencies, individuals having A allele in 1154G>A polymorphic region have been found to have
signicantly increased risk for the dened diseases.
On the other hand, in another study from Northern China on 344 women with endometriosis and 360 healthy controls
by Liu et al. [14], AA genotype of the -1154G>A polymorphic region was alleged to decrease the risk of endometriosis.
The frequency of AA genotype of the -1154G>A polymorphic region was 1.7% in patients and 5.8% in controls while
the frequency of harboring A allele was 16.1% in patients and 22.2% in controls concluding a statistically signicant
reduction of endometriosis risk in case of A allele of -1154G>A polymorphism.
Perini at al. [13] did not report an association between endometriosis and VEGF gene -2578C>A polymorphisms.
Similarly, in our study the frequency of CC genotype of -2578C>A polymorphism was 38.5% in patients and 24.6% in
controls, and the frequency of AC + CC genotype was 86.2% in patients and 72.3% in controls. Despite being more
frequent in patients, the difference was not statistically signicant (p = 0.083). As for the C allele, the frequency was
62.3% in patients and 48.5% in controls which established a statistically signicant difference (p A
polymorphic region and an approximate 2 fold increased risk in AC+CC genotype and C allele. Also, Liu et al. [14]
reported frequencies of AA, CA, and CC genotypes and A allele frequency of -2578C>A polymorphic region in patient
and control groups respectively; 3.2% - 8.1%; 32.0% - 36.4%, and 64.8% - 55.6%, 19.2% - 26.3% concluding a
statistically signicant difference in terms of genotype and allele harbouring (p C, +936C>T polymorphic region our results suggest no signicant effect on the
susceptibility to HMB. It is noteworthy that our results are consistent with Perini’s study [13] and Zhao and colleagues
[15] which consist a larger number (958 cases and 959 controls) of Australian women. Similarly Liu et al. [14] found
that the + 936C>T polymorphic region does not have a signicant relationship with the risk of developing
endometriosis.
The main reason for these inconsistent results may be the differences between ethnic groups. For example, the
Ensembl database shows that the frequency of the VEGF -2578 A allele was 27.2% with the CHB (Han Chinese in
Beijing), 34.1% with AMR (American), and 45.5% with CEU (Utah Residents with Northern and Western European
Ancestry).
In the literature, we found two studies from our country evaluating the effect of VEGF gene +405G>C polymorphism
on endometriosis risk with controversial results. Altınkaya et al. [16] evaluated the genotype frequencies of VEGF
+405G>C polymorphic regions on 98 endometriosis patients and 94 controls. They detected GC genotype in 58.2% of
Page 7/14
patients and 10.6% of controls and G allele in 45.4% of patients and 5.3% of controls. They suggested that GC
genotype and G allele may be associated with the advanced grade endometriosis risk in the Turkish population. In
another study from Turkey, Attar et al. [17.] also proposed that CC genotype of +405G>C polymorphisms may be
related to endometriosis whereas G allele has a protective role against endometriosis. The small sample sizes impede
with reecting data of the whole Turkish population and may partially explain the conicting results.
The meta-analyses also yielded conicting results. In a meta-analysis evaluating 14 eligible studies on a total of 3313
endometriosis patients and 3393 controls, VEGF gene -1154G>A polymorphic region GA genotype and A allele and
-2578C>A polymorphic region CC genotype and C allele were found to reduce endometriosis risk whereas +936C>T
poymorphic region CT genotype and T allele increased the risk similar to our results on HMB [18]. No effect of the
+405G>C polymorphism was reported in line with our ndings. On the contrary, Jiang et al. [19] stated that VEGF +
405G>C and + 936C>T SNPs may be associated with the risk of endometriosis in their meta-analysis, in which they
investigated 9 studies including 1610 endometriosis patients and 1643 control cases.
The most important limitation of the current study is the small sample size which can also be held responsible for the
controversial results in other studies in the literature. Besides, the facts that these studies have been performed on
distinct ethnic groups and different diseases and having identied various haplotypes may have led to the conicting
results. These diverse results suggest that disease tendency may stem from not solely a single polymorphism but a
combined effect of polymorphisms and that haplotype effect may play a more signicant role in disease tendency
than single polymorphisms.
In our study in the examination of the -2578C>A, -1154G>A,+405G>C and 534C> T polymorphic regions of the VEGF
gene we have identied 4 haplotypes: CACC (38.1%), AGGC (31.2%), CAGC (17.3%), AAGT (12.3%). AGGC haplotype
was less prevalent in HMB patients (23.8% vs 38.5%) while CAGC haplotype was more frequent in the HMB group
(25.4% vs 9.2%). Perini et al. [13] emphasized that CCGG haplotype derived from four polymorphisms (-2578C>A /
-460T>C / -1154G>A / + 405G>C) has a protective effect against the development of endometriosis (3% in cases, 6.7%
in the control group). Liu et al. [14] stated that the VEGF gene -460C>T -1154G>A, -2578C>A regions included CAA, TAA
and TAC haplotypes can signicantly reduce the risk of developing endometriosis, and the CAC haplotype can
signicantly increase the risk of developing endometriosis. The polymorphic regions included in the studies produced
different linkage disequilibrium results and different haplotypes were obtained in each study making it dicult to
compare study results.
Our study on VEGF gene polymorphisms in Turkish women with HMB suggests increased risk for C allele, CC, and
AC+CC genotypes of −2578A>C polymorphic region, A allele, AA genotype, and CAGC haplotype of the −1154G>A
polymorphic region whereas protective role of the AGGC haplotype. However, further studies with a larger sample size
are required to gure out a more certain association.
Declarations
Author Contribution
İ Kaygusuz: Project development, Data collection, Data analysis, Manuscript writing, editing
N Semerci Gündüz: Project development, reduction, editing
I. Ethical approval: The study was approved by the Ankara Yıldırım Betazıt University Human Ethical Committee
II. Funding details (In case of Funding): No funding
Page 8/14
III. Conict of interest: The authors declare that they have no conict of interest.
IV. Informed Consent: Signed informed consent was obtained from all patients before starting study.
References
1. Mints M, Blomgren B, Falconer C, Fianu-Jonasson A, Palmblad J (2005) Microvascular density, vascular
endothelial growth factor A, and its receptors in endometrial blood vessels in patients with menorrhagia. Fertil
Steril 84(3):692-700. https://doi.org/10.1016/j.fertnstert.2005.03.065
2. Elkilani OA, Soliman MA (2017) Angiogenesis mediators in women with idiopathic heavy menstrual bleeding. Int
J Gynaecol Obstet 136(3):280-284. https://doi.org/10.1002/ijgo.12068
3. Biswas Shivhare S, Bulmer JN, Innes BA, Hapangama DK, Lash GE (2018) Endometrial vascular development in
heavy menstrual bleeding: altered spatio-temporal expression of endothelial cell markers and extracellular matrix
components. Hum Reprod 33(3):399-410. https://doi.org/10.1093/humrep/dex378
4. Kuzmina N, Palmblad J, Mints M (2011) Predictive factors for the occurrence of idiopathic menorrhagia: evidence
for a hereditary trait. Mol Med Rep 4(5):935-939. https://doi.org/10.3892/mmr.2011.514
5. Andersson E, Zetterberg E, Vedin I, Hultenby K, Palmblad J, Mints M (2015) Low pericyte coverage of endometrial
microvessels in heavy menstrual bleeding correlates with the microvessel expression of VEGF-A. Int J Mol Med
35(2):433-438. https://doi.org/10.3892/ijmm.2014.2035
. Mansour D, Hofmann A, Gemzell-Danielsson K (2021) A Review of Clinical Guidelines on the Management of Iron
Deciency and Iron-Deciency Anemia in Women with Heavy Menstrual Bleeding. Adv Ther 38(1):201-225.
https://doi.org/10.1007/s12325-020-01564-y
7. Fraser IS, Critchley HO, Munro MG, Broder M, Writing Group for this Menstrual Agreement Process (2007) A
process designed to lead to international agreement on terminologies and denitions used to describe
abnormalities of menstrual bleeding. Fertil Steril 87(3):466-476. https://doi.org/10.1016/j.fertnstert.2007.01.023
. Mints M, Hultenby K, Zetterberg E, Blomgren B, Falconer C, Rogers R, Palmblad J (2007) Wall discontinuities and
increased expression of vascular endothelial growth factor-A and vascular endothelial growth factor receptors 1
and 2 in endometrial blood vessels of women with menorrhagia. Fertil Steril 88(3):691-697.
https://doi.org/10.1016/j.fertnstert.2006.11.190
9. Mints M, Blomgren B, Palmblad J (2010) Expression of angiopoietins 1, 2 and their common receptor tie-2 in
relation to the size of endothelial lining gaps and expression of VEGF and VEGF receptors in idiopathic
menorrhagia. Fertil Steril 94(2):701-707. https://doi.org/10.1016/j.fertnstert.2009.03.042
10. Munro MG, Critchley HO, Broder MS, Fraser IS, FIGO Working Group on Menstrual Disorders (2011) FIGO
classication system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of
reproductive age. Int J Gynaecol Obstet 113(1):3-13. https://doi.org/ 1016/j.ijgo.2010.11.011
11. Higham JM, O’Brien PM, Shaw RW (1990) Assessment of menstrual blood loss using a pictorial chart. Br J
Obstet Gynaecol 97:734-739. https://doi.org/10.1111/j.1471-0528.1990.tb16249.x
12. Zakherah MS, Sayed GH, El-Nashar SA, Shaaban MM (2011) Pictorial blood loss assessment chart in the
evaluation of heavy menstrual bleeding: diagnostic accuracy compared to alkaline hematin. Gynecol Obstet
Invest 71: 281-284. https://doi.org/10.1159/000320336
13. Perini JA, Cardoso JV, Berardo PT, Vianna-Jorge R, Nasciutti LE, Bellodi-Privato M, Machado DE, Abrão MS (2014)
Role of vascular endothelial growth factor polymorphisms (-2578C>A, -460 T>C, -1154G>A, +405G>C and
Page 9/14
+936C>T) in endometriosis: a case-control study with Brazilians. BMC Womens Health 14:117. https://doi.org/
1186/1472-6874-14-117
14. Liu Q, Li Y, Zhao J, Sun DL, Duan YN, Wang N, Zhou RM, Kang S (2009) Association of polymorphisms -1154G/A
and -2578C/A in the vascular endothelial growth factor gene with decreased risk of endometriosis in Chinese
women. Hum Reprod 24(10):2660-2666. https://doi.org/10.1093/humrep/dep208
15. Zhao ZZ, Nyholt DR, Thomas S, Treloar SA, Montgomery GW (2008) Polymorphisms in the vascular endothelial
growth factor gene and the risk of familial endometriosis. Mol Hum Reprod 14(9):531-538.
https://doi.org/10.1093/molehr/gan043
1. Altinkaya SO, Ugur M, Ceylaner G, Ozat M, Gungor T, Ceylaner S (2011) Vascular endothelial growth factor +405
C/G polymorphism is highly associated with an increased risk of endometriosis in Turkish women. Arch Gynecol
Obstet 283(2):267-72. https://doi.org/10.1007/s00404-009-1344-1
17. Attar R, Agachan B, Kuran SB, Toptas B, Eraltan IY, Attar E, Isbir T (2010) Genetic variants of vascular endothelial
growth factor and risk for the development of endometriosis. In Vivo 24(3):297-301.
1. Li YZ, Wang LJ, Li X, Li SL, Wang JL, Wu ZH, Gong L, Zhang XD (2013) Vascular endothelial growth factor gene
polymorphisms contribute to the risk of endometriosis: an updated systematic review and meta-analysis of 14
case-control studies. Genet Mol Res 12(2):1035-44. https://doi.org/10.4238/2013.April.2.20
19. Jiang Y, Tang JY, Wu Y, Zhao TF (2012) Vascular endothelial growth factor gene polymorphisms and the risk of
endometriosis: a systematic review. Zhonghua Fu Chan Ke Za Zhi 47(3):179-84.
Tables
Table 1. Primers, amplicon size and usage purposes
Page 10/14
Primer Orientation Sequencing Genotyping Ampliconsize (bp) Sequence (5'-3')
VEGFA_SNP2_F Forward Exon 1 SNP 2
SNP 3
SNP 5
1500 CGGATGGGTAATTTTCAGGCTGTG
VEGFA_1R Revers CCTCCCCCTGCACCTAAGACGAC
VEGFA_2F Forward Exon 2 - 468 GGGAAGTGTGGGGAAGGTACAGG
VEGFA_2R Revers CTTCCCCTTCCTCCCCACAGTTC
VEGFA_3F Forward Exon 3 - 433 GAAGCTCCAAAGAGTGGCATTACAG
VEGFA_3R Revers ACCATACCTCCCCTGTGCAACTC
VEGFA_4-5F Forward Exon 4
Exon 5
- 975 AGGAGTCAGGGTGAAGCCTAGAGAG
VEGFA_4-5R Revers CACTAGCCCTAGAGCCATCATCCTG
VEGFA_6F Forward Exon 6 - 398 AGAGACCACCTGCCTCCTGACAC
VEGFA_6R Revers TCTACCCGTTGGTGCCAATTAGTG
VEGFA_7F Forward Exon 7 - 429 CTGTAGCGCTCGGATCCTTCCAG
VEGFA_7R Revers ACCAGGCAGGCAGCTAGAAACTGAG
VEGFA_8F Forward Exon 8 SNP 4 463 CCTTCCTGTCCTCTCTGCTCTTATGG
VEGFA_8R Revers ATCTTCCGGGCTCGGTGATTTAG
VEGFA_SNP1_F Forward - SNP 1 250 CTGGAGCGTTTTGGTTAAATTGAGG
VEGFA_SNP1_R Revers CCCCATCCCATTCTTGCATATAGG
Table 2: Baseline characteristics of study subjects
Page 11/14
Variables HMB group (n=65) Control group (n=65) t/z c2 p
Age (year) 30.58 ± 7.06 29.08 ± 6.56 t=1.261 0.210
Body Mass Index (kg/m2) 22.35 ± 2.57 22.77 ± 2.65 t=0.923 0.358
Marital status
Married 43 (% 66.2) 40 (% 61.5) c2 =0.300 0.584
Unmarried 22 (% 33.8) 25 (% 38.5)
Gravidity 1 (2) 1 (1) Z=-1.361 0.180
Parity 1 (2) 1 (2) Z=-1.185 0.290
Age at menarche (year) 13 (2) 13 (1) Z=-1.311 0.190
Menses duration (days) 7 (2.5) 5 (2) Z=5.339 <0.001*
Length of Menstrual cycle (day) 28 (3) 28 (2) Z=0.320 0.749
PBAC score 258 (246) 50 (44) Z=9.937 <0.001
Abbreviations: PBAC, Pictorial Blood Loss Assessment Chart
Data are mean ± SD, median (IQR) or numbers (n) and percentages (%)
t= Student’s t test, Z=Mann–Whitney U-test, c2 = Chi-square
* p values ≤ 0.05 were considered statistically signicant
Table 3. Logistic regression analysis of associations between VEGF polymorphisms and risk of HMB
Page 12/14
AMK-E grup,
n = 65 (%)
Kontrol grup,
n = 65 (%)
OR (95% CI) p
rs699947 (−2578A>C)
AA 9 (13.8) 18 (27.7) Referans
AC 31 (47.7) 31 (47.7) 1.97 (0.77-5.29) 0.15
CC 25 (38.5) 16 (24.6) 3.05 (1.11-8.84) 0.03*
AC+CC 56 (86.2) 47 (72,3) 2.35 (0.97-6.0) 0.05*
A Alel 49 (37.7) 67 (51.5) Referans
C Alel 81 (62.3) 63 (48.5) 1.75 (1.07-2.88) 0.02*
rs1570360 (−1154G>A)
GG 3 (4.6) 10 (15.4) Referans
GA 25 (38.5) 30 (46.2) 2.13 (0.53-11.20) 0.26
AA 37 (56.9) 25 (38.5) 3.49 (0.89-18.10) 0.06*
GA+AA 62 (95.4) 57(87.7) 2.07 (0.56-10.32) 0.26
G Alel 31 (23.8) 50 (38.4) Referans
A Alel 99 (76.1) 80 (61.5) 1.74 (1.01-3.01) 0.04*
rs2010963 (+405G>C)
CC 9 (13.8) 9 (13.8) Referans
CG 30 (46.2) 33 (50.8) 0.91 (0.31-2.66) 0.85
GG 26 (40.0) 23 (35.4) 1.12 (0.37-3.41) 0.82
CG+GG 56 (86.2) 56 (86.2) 0.99 (0.33-2.78) 1.00
C Alel 48 (36.9) 51 (39.2) Referans
G Alel 82 (63.1) 79 (60.8) 1.10 (0.66-1.82) 0.70
rs3025039 (+936C>T)
CC 49 (75.4) 43 (66.2) Referans
CT 15 (23.1) 20 (30.8) 0.66 (0.29-1.45) 0.29
TT 1 (1.5) 2 (3.1) 0.46 (0.01-5.98) 0.49
CT+TT 16 (24.6) 22 (33.9) 0.64 (0.29-1.37) 0.24
C Alel 113 (86.9) 106 (81.5) Referans
T Alel 17 (13.1) 24 (18.5) 0.66 (0.33-1.30) 0.23
rs25648 (c.534C>T)
CC 49 (75.4) 51 (78.5) Referans
CT 16 (24.6) 12 (18.5) 0.72 (0.31-1.68) 0.18
Page 13/14
TT 0 2 (3.1) - -
CT+TT 16 (24.6) 14 (21.6) 0.84 (0.37-1.90) 0.68
C Alel 114 (87.7) 114 (87.7) Referans
T Alel 16 (12.3) 16 (12.3) 1 (0.47-2.12) 1.00
Abbreviations: OR, odds ratio; CI, condence interval.
* p values ≤ 0.05 were considered statistically signicant
Table 4. Haplotype distributions of VEGF gene polymorphisms rs699947, rs1570360, rs2010963, and rs25648
Haplotype Frequency (%) HMB group, n=65 (%) Control group, n=65 (%) P OR (95% CI)
CAAC 38.1 48 (36.9) 51 (39.2) 0,737 0.918 (0.555-1.517)
AGGC 31.2 31 (23.8) 50 (38.5) 0,012* 0.505 (0.295-0.864)
CAGC 17.3 33 (25.4) 12 (9.2) 0,0005* 3.387 (1.659-6.917)
AAGT 12.3 16 (12.3) 16 (12.3) 0.981 1.009 (0.481-2.116)
Abbreviations: OR, odds ratio; CI, condence interval.
* p values ≤ 0.05 were considered statistically signicant
Figures
Page 14/14
Figure 1
Linkage disequilibrium plot created by Haploview 4.2
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.